Back to Insights
    RegulatoryClinical OverviewWell-Established UseArticle 10aEU MAA
    Share on LinkedIn

    Well-Established Use Applications: Building a Bibliographic Clinical Overview That Holds Up

    October 5, 20266 min readUpdated
    Neta Kela, PhDWritten byNeta Kela, PhDFounder & Managing PartnerFeature image for the PXM article: Well-Established Use Applications: Building a Bibliographic Clinical Overview That Holds Up

    Short answer: A well-established use application under Article 10a replaces your own preclinical and clinical studies with published scientific literature. That makes the Clinical Overview the core of the file. It must show at least ten years of well-established medicinal use of the active substance in the EU, recognised efficacy and an acceptable level of safety, and it must bridge your specific product to the products studied in the literature.

    When does Article 10a apply?

    Article 10a of Directive 2001/83/EC allows an applicant to rely on bibliographic data when the active substance has been in well-established medicinal use within the EU for at least ten years. Annex I, Part II sets out the factors assessors consider: the time over which the substance has been used, quantitative aspects of use, the degree of scientific interest reflected in published literature, and the coherence of scientific assessments.

    The ten-year period runs from the first systematic and documented use of the substance as a medicinal product in the EU. It is not the same as the time since first authorisation of any one product.

    What makes a bibliographic Clinical Overview strong?

    1. A documented literature strategy. State the databases searched, the search terms, the date range and the inclusion and exclusion criteria. Assessors need to see that the literature was searched systematically, not selected to fit a conclusion.
    2. Critical appraisal, not a reference list. Assess each key study for design, population, dose, comparator and quality. Weak or conflicting studies must be discussed, not left out.
    3. A clear bridge to your product. The published studies used specific formulations, doses and populations. The overview must explain why those results apply to your product, including any differences in formulation or route, and whether those differences affect bioavailability.
    4. Gaps addressed openly. If the literature does not cover a population or indication you propose, either narrow the claim or justify the extrapolation. An unaddressed gap is a predictable assessor question.
    5. Product information consistent with the evidence. Every claim in the proposed SmPC should trace to the evidence discussed in the overview.

    Common mistakes

    • Relying on review articles instead of the primary studies behind them
    • Literature that supports the substance but not the proposed indication or dose
    • No discussion of safety data from post-marketing experience
    • A Nonclinical Overview that is treated as a formality, when it must also assess published toxicology and pharmacology

    Sources

    • EUPATI: Well-established use application: https://learning.eupati.eu/mod/book/view.php?id=908&chapterid=877
    • BfArM: Bibliographical application: https://www.bfarm.de/EN/Medicinal-products/Licensing/Types-of-marketing-authorisation/Bibliographical-application/_node.html
    • EMA: Pre-authorisation guidance: https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/pre-authorisation-guidance

    Frequently Asked Questions

    How PXM Helps With This

    Related

    Part of FDA & CMC Readiness. Start from the pillar: Operate practice, FDA Regulatory Readiness, CMC & Manufacturing, FDA Expedited Pathways, EU Regulatory Pathways

    Get notified when we publish new funding and regulatory guides

    Practical guidance on FDA and EMA strategy, CMC readiness, and non-dilutive funding — sent only when there is something worth reading.